Hua MedicineHUMDF 46 PB Ratio is 2.38 as of Jun. 29, 2026, which is 77% below its 10-year median of 10.18. GuruFocus rates HUMDF with a GF Score™ of 46/100 and a GF Value™ of $1.46 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 922 Drug Manufacturers companies, Hua Medicine ranks worse than 51.84% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-29), Hua Medicine's share price is $0.3401. Hua Medicine's Book Value per Share for the quarter that ended in Dec. 2025 was $0.14. Hence, Hua Medicine's PB Ratio of today is 2.38.
Good Sign:
Hua Medicine stock PB Ratio (=1.78) is close to 5-year low of 1.78.
The historical rank and industry rank for Hua Medicine's PB Ratio or its related term are showing as below:
HUMDF'
s PB Ratio Range Over the Past 10 Years
Min: 1.78 Med: 10.18 Max: 20.88
Current: 1.78
During the past 10 years, Hua Medicine's highest PB Ratio was 20.88. The lowest was 1.78. And the median was 10.18.
HUMDF's PB Ratio is ranked worse than 51.84% of 922
companies
in the Drug Manufacturers industry
Industry Median: 1.845
vs HUMDF: 1.78
During the past 3 years, the average Book Value Per Share Growth Rate was 51.30% per year.
During the past 10 years, the highest 3-Year average Book Value Per Share Growth Rate of Hua Medicine was 51.30% per year. The lowest was -50.10% per year. And the median was -33.35% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Hua Medicine PB Ratio Related Terms
Hua Medicine PB Ratio Historical Data
* Premium members only.
The historical data trend for Hua Medicine's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Hua Medicine's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hua Medicine PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hua Medicine's PB Ratio distribution charts can be found below:
* The bar in red indicates where Hua Medicine's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Hua Medicine's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Hua Medicine (HUMDF) has a PB Ratio of 2.38 as of Jun. 29, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Hua Medicine and its competitors. This is 77% below median its historical median of 10.18. Over the past decade, Hua Medicine's PB Ratio has ranged from 1.78 to 20.88. According to the industry distribution chart, Hua Medicine ranks #478 out of 922 companies in the Drug Manufacturers industry, placing it in the top 51.8%.
Is Hua Medicine's PB Ratio too high?
Hua Medicine's current PB Ratio of 2.38 is 77% below median its 10-year median of 10.18. Over the past 10 years, this metric has ranged from a low of 1.78 to a high of 20.88. The Drug Manufacturers industry median PB Ratio is 1.85. Hua Medicine's value of 2.38 is 29% above this industry median. Based on the distribution chart, Hua Medicine ranks #478 out of 922 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Hua Medicine has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Hua Medicine's PB Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Hua Medicine ranks #478 out of 922 companies for PB Ratio. This places Hua Medicine in the lower half of its industry. The industry median PB Ratio is 1.85. Hua Medicine's value of 2.38 is 29% above this benchmark. Historically, Hua Medicine's own PB Ratio has ranged from 1.78 to 20.88 over the past decade. While the company's 10-year median is 10.18 vs. the industry median of 1.85, Hua Medicine has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.85, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hua Medicine's current PB Ratio of 2.38 is 29% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Hua Medicine and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hua Medicine's current PB Ratio is 2.38, which is 77% below median its own 10-year median of 10.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hua Medicine stock overvalued right now?
Based on GuruFocus' analysis, Hua Medicine (HUMDF) is currently considered Possible Value Trap. The stock's GF Value™ is $1.46, compared to a current price of $0.34 — trading 76.7% below its estimated fair value. The current PB Ratio is 2.38, which is 77% below median its 10-year median of 10.18 and 29% above the Drug Manufacturers industry median of 1.85. Hua Medicine's overall GF Score™ is 46/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Hua Medicine (HUMDF), the current PB Ratio is 2.38 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hua Medicine (HUMDF) Overvalued in 2026?
Based on GuruFocus' analysis, Hua Medicine stock appears to be undervalued.
The current stock price of $0.34 is trading 76.7% below its estimated GF Value™ of $1.46.
GuruFocus considers Hua Medicine to be Possible Value Trap.
Key valuation signals for HUMDF:
PB Ratio: 2.38 (77% below median its 10-year median of 10.18)
GF Value™: $1.46 vs. price of $0.34 (76.7% below fair value)
Industry Position: 29% above the Drug Manufacturers median (#478 of 922)
No single metric tells the full story. See the HUMDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hua Medicine is an investment holding company. It is engaged in the development and commercialization of a first-in-class oral drug, Dorzagliatin (HMS5552), for the treatment of Type 2 diabetes. Dorzagliatin is a first-in-class glucokinase activator, or GKA, designed to control the progressive degenerative nature of diabetes by restoring glucose homeostasis in Type 2 diabetes. The group majorly operates and generates the majority of its revenue from the PRC.
46GF Score
Get the complete analysis for HUMDF
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HUMDF has been successfully added to your 
